“Asia Fashion Fair” เตรียมเปิดฉากที่นาโกย่า อ้าแขนต้อนรับผู้ร่วมแสดงสินค้าจากทั่วโลก

          งานแสดงสิ่งทอและเครื่องนุ่งห่ม "Asia Fashion Fair" (AFF) ครั้งที่ 28 จะจัดขึ้นที่ศูนย์แสดงสินค้าและอุตสาหกรรมแห่งเมืองนาโกย่า ในบริเวณฟูคิอาเกะฮอลล์ ระหว่างวันที่ 5-7 กรกฎาคม 2559 มหกรรมนี้จัดโดยบริษัท AFF Co., Ltd. ร่วมกับ Japan-China Economic Relations and Trade Center และดำเนินการโดยคณะกรรมการจัดงาน AFF

          AFF เป็นงานแสดงสิ่งทอและเครื่องนุ่งห่มจากผู้ผลิตแบบ OEM-ODM ที่ยิ่งใหญ่และเป็นมืออาชีพที่สุด โดยมีผลิตภัณฑ์หลากหลายประเภท อาทิ เสื้อผ้าสำเร็จรูป เครื่องประดับตกแต่ง เคหะสิ่งทอ ผ้าผืน วัสดุอุปกรณ์ต่างๆ และอีกมากมาย งานนี้เปิดตัวเป็นครั้งแรกเมื่อปี 2546 และจัดขึ้นปีละ 3 ครั้ง โดยทุกปีจะมีผู้ซื้อกว่า 10,000 รายเข้าร่วมงาน จนกลายเป็นมหกรรมที่ "พลาดไม่ได้" สำหรับคนในอุตสาหกรรมสิ่งทอและเครื่องนุ่งห่มของญี่ปุ่น ทั้งนี้ ข้อมูลสถิติในปีที่ผ่านๆมาระบุว่า ผู้ซื้อมากถึง 85% ใช้เวลาในการเจรจาธุรกิจในงานนี้อย่างน้อย 1 ชั่วโมง

          เมืองนาโกย่า เป็นศูนย์กลางของเขตมหานครที่ใหญ่เป็นอันดับ 3 ของญี่ปุ่นที่เรียกว่าเขตมหานครชูเกียว โดยเป็นที่ตั้งของบริษัทผู้ผลิตมากมาย ส่วนฟูคิอาเกะฮอลล์ ในศูนย์แสดงสินค้าและอุตสาหกรรมแห่งเมืองนาโกย่านั้น ถือเป็นสถานที่สำคัญในการจัดกิจกรรมทางธุรกิจต่างๆ และสามารถเดินทางไปมาได้อย่างสะดวกสบาย

          สมัครเข้าร่วมงานและรับข้อมูลเพิ่มเติมได้ที่เว็บไซต์ของ AFF ( www.asiafashionfair.jp )

          อีเมล: info@asiafashionfair.jp

          สื่อมวลชนติดต่อ:

          Mr. Huang
          มือถือ: +86-10-6528-5310
          อีเมล: huangyuchen@chinatex.com

Asia Fashion Fair - NAGOYA 2016 Invites Exhibitors Worldwide to Join Our Business Party

         

The 28th AFF (Asia Fashion Fair) - NAGOYA will take place at Nagoya Trade & Industry Center, Fukiage Hall from July 5th to 7th, 2016. The fair is hosted by AFF Co., Ltd. and Japan-China Economic Relations and Trade Center, and implemented by the AFF Organizing Committee.

          AFF is the biggest and the most professional Clothing & Textile OEM - ODM fair for a variety of products, such as ready-made garments, accessories, home-textiles, fabrics and auxiliary materials in Japan. Started in 2003, it has been held three times a year. Every year there are more than 10,000 buyers visiting AFF, which makes it a"must-go" business party in Japan's textile and clothes industry. According to historical data, 85% of buyers stayed at least one hour on-site for business discussion.

          Nagoya, the center of Japan's third-largest metropolitan region, has a large number of manufacturing enterprises. Conveniently-located Nagoya Trade & Industry Center, Fukiage Hall is an important place for business activities.

          Visit the AFF website ( www.asiafashionfair.jp ) now for an application and more information.

          Email: info@asiafashionfair.jp

          Media contact:

          Mr. Huang
          Cell Number: +86-10-6528-5310
          Email: huangyuchen@chinatex.com  

"เมืองคุราชิกิ" ของญี่ปุ่นเผยคลิปวิดีโอ "Denim Ninja Kurashiki"

          เมืองคุราชิกิ ในจังหวัดโอกายามะ ทางภาคตะวันตกของญี่ปุ่น เปิดตัวคลิปวิดีโอชุด "Denim Ninja in Kurashiki" สำหรับนักท่องเที่ยว เพื่อดึงดูดนักท่องเที่ยวจากต่างประเทศ โดยเมืองคุราชิกิเป็นที่รู้จักในฐานะถิ่นกำเนิดของผ้าเดนิมญี่ปุ่น

          วิดีโอแนวแอคชั่นเคลื่อนไหวอย่างรวดเร็วนี้นำเสนอเรื่องราวของนินจาผู้หนึ่งที่ถูกส่งตัวออกจากเมืองหลวงเพื่อไปสำรวจ "ความลับ" 30 ประการของเมืองคุราชิกิ โดยมีเป้าหมายเพื่อให้นักท่องเที่ยวจากไต้หวัน (ฮ่องกงและไทย) ได้รู้สึกเพลิดเพลินขณะใช้เวลาอยู่ในเมืองนี้มากที่สุด

          คุราชิกิตั้งอยู่ระหว่างฮิโรชิมาและโอซากา และสามารถเดินทางจาก 2 เมืองดังกล่าวด้วยรถไฟ "ชินคันเซ็น" ในเวลาประมาณ 1 ชั่วโมง ขณะนี้เมืองคุราชิกิมีแผนจะจ้างเจ้าหน้าที่ที่สามารถสื่อสารภาษาอังกฤษได้ เพื่อที่นักท่องเที่ยวจากไต้หวัน (ฮ่องกงและไทย) จะได้เพลิดเพลินไปกับสถานที่ต้องมนตร์ขลังและเต็มไปด้วยประวัติศาสตร์แห่งนี้ได้ดียิ่งขึ้น

          นินจาในชุดเดนิม "Denim Ninja" จะเยือนคุราชิกิ เพื่อไขความลับ 30 ประการของเมืองนี้ ร่วมค้นหาคำตอบไปพร้อมๆกับนินจาผู้นี้ในขณะที่เขาออกสำรวจไปทั่วเมือง…

           https://www.kurashiki-tabi.jp/extra/ninjya/en/index.html

          (ภาษาจีนดั้งเดิม)
          DENIM NINJA in KURASHIKI - DENIM NINJA ไขความลับ 30 ประการของเมืองคุราชิกิ!
          (เวอร์ชันยาว)
           https://www.youtube.com/watch?v=0hsACZhKZA8

          (ภาษาไทย)
          DENIM NINJA in KURASHIKI - DENIM NINJA ไขความลับ 30 ประการของเมืองคุราชิกิ!
          (เวอร์ชันยาว)
           https://www.youtube.com/watch?v=FIPXL1tOQrY

Japan's Kurashiki City Releases Series of "Denim Ninja in Kurashiki" Videos

          Kurashiki City in Okayama Prefecture, western Japan, has released "Denim Ninja in Kurashiki," a series of video clips for tourists, to attract travelers from abroad. Kurashiki is known as the birthplace of Japanese denim fabric.

          The fast-paced action videos present a ninja dispatched from the capital to investigate 30 "mysteries" of Kurashiki. They aim to ensure that tourists from Taiwan (Hong Kong, Thailand) get the most enjoyment out of their time while in the city.

          Kurashiki is situated between Hiroshima and Osaka, and can be reached from either city in approximately one hour by "shinkansen" bullet train. Plans are underway to employ English-speaking staff so that visitors from Taiwan (Hong Kong, Thailand) can better enjoy this charming place, steeped in history.

          Clad in the local denim, the "Denim Ninja" makes a visit to solve the 30 mysteries in Kurashiki. Join him as he appears throughout the town in search of answers....

           https://www.kurashiki-tabi.jp/extra/ninjya/en/index.html

          (Chinese, traditional)
          DENIM NINJA in KURASHIKI - DENIM NINJA solves the 30 mysteries of Kurashiki!
          (long ver.)
           https://www.youtube.com/watch?v=0hsACZhKZA8

          (Thai)
          DENIM NINJA in KURASHIKI - DENIM NINJA solves the 30 mysteries of Kurashiki!
          (long ver.)
           https://www.youtube.com/watch?v=FIPXL1tOQrY

Anbang-J.C. Flowers-Primavera Consortium Determines not to Proceed with Its Proposal to Acquire Starwood

          Anbang Insurance Group Co., Ltd., together with its partners J.C. Flowers & Co. and Primavera Capital Limited, (collectively, "the Consortium" ), today announced that the Consortium has determined not to proceed with its proposal to acquire Starwood Hotels & Resorts Worldwide, Inc. (NYSE: HOT) ("Starwood").

          The Consortium issued the following statement:

          "We were attracted to the opportunity presented by Starwood because of its high-quality, leading global hotel brands, which met many of our acquisition criteria, including the ability to generate consistent, long-term returns over time.  However, due to various market considerations, the Consortium has determined not to proceed further.  We thank the Starwood Board, management team and its advisors for their efforts and support throughout this process."

          About Anbang Insurance Group 

          Anbang Insurance Group Co., Ltd. is a comprehensive insurance company, based in China, with a global network of over 35 million customers. Anbang's business areas cover life insurance, property and casualty insurance, health insurance, pensions, banking and asset management. Anbang remains well positioned through the strength of our leading international franchises and their growth potential.  We look forward to continuing to execute on opportunities to meet our long-term value-driven strategic goals.

          About J.C. Flowers & Co.

          J.C. Flowers & Co. is a leading private investment firm dedicated to investing globally. Founded in 1998, J.C. Flowers & Co. includes, among others, a SEC registered investment adviser, J.C. Flowers & Co. LLC, that manages private equity funds, a broker dealer, J.C. Flowers Securities Co. LLC, that is SEC registered and a FINRA member and a fixed income asset management platform, J.C. Flowers Asset Management LLC.

          About Primavera Capital Limited

          Primavera Capital ("Primavera") is a leading Asia-based investment firm. The firm employs a flexible strategy of growth capital and control-oriented investments and seeks to create long-term value by working closely with portfolio companies to improve operational efficiency, competitiveness, and earnings growth. Founded by Dr. Fred Hu, a renowned economist and successful investor, and a former partner and Chairman of Greater China at Goldman Sachs Group, the Primavera team combines global capital market experience, deep industry knowledge, and a strong network of relationships with policy-makers/regulators as well as leading CEOs and entrepreneurs in Asia and globally.

          Contacts

          Joele Frank / Andy Brimmer / Jonathan Keehner / Adam Pollack
          Joele Frank, Wilkinson Brimmer Katcher
          212-355-4449

UnionPay International and Airports in Malaysia Join Forces to Reward Shoppers

          - Global payments company launches gift-with-purchase promotions in Kuala Lumpur, Penang and Langkawi airports.

          UnionPay Cardholders will have a chance to own intricate hand-finished gifts rich in Malaysian heritage when they shop at four Malaysian airports from 1 April 2016. Cardholders with card numbers starting with "62" can look forward to free Royal Selangor pewter products when they spend above RM500.

         

Senior General Manager of MAHB Encik Mohammad Nazli & General Manager of UPI Southeast Asia Mr. Wenhui Yang launching the Malaysian airport promotion.

          Shoppers in Penang International Airport and Langkawi International Airport need only spend a minimum of RM500 to receive a complimentary pewter chopstick rest from Malaysia pewter icon Royal Selangor. Shoppers in KLIA and KLIA2 can look forward to a complimentary Royal Selangor name card holder with a minimum spending of RM1,500.

          To claim their gifts, shoppers can accumulate up to three same-day receipts to redeem these exclusive gifts at the respective airports. This gift-with-purchase promotion runs from 1 April 2016 to 30 June 2016.

          Mr Wenhui Yang, General Manager of UnionPay International Southeast Asia said, "Last year, we partnered MAHB for a 3 month promotion in KLIA2 and it was very successful, with more than double in year-on-year growth for transactions volume. That's why we are pleased to make it bigger and better this time, extending the promotion to include KLIA, Penang International Airport, and Langkawi International Airport."

          "This year's campaign is launched at a time when we are seeing a surge of tourists visiting Malaysia. Passenger traffic at the four airports alone was 57 million in 2015," added Mr Yang.

          He explained why UPI chose Royal Selangor pewter as gifts. "Royal Selangor is Malaysia's premier purveyor of quality pewter and a recognised brand worldwide. The brand has collaborated with international luxury names and remains a hallmark of Malaysian craftsmanship. Visitors and locals alike will be excited to receive such a gift. We at UnionPay strive to always bring the best to our customers in the countries that we operate in," said Mr Yang.

          Mr Yang believed UPI and Malaysian tourism make good partners too. "Asia Pacific is the second-most preferred destination in the world, with substantial potential for further growth. Growing alongside Malaysia's tourism rates are travellers who prefer to use UnionPay when making purchases. The acceptance rates of UnionPay cards at local ATMs are over 90%, and merchant acceptance rates are planned to increase this year."

          The strengthening acceptance of UnionPay cards in Malaysia solidifies the importance of this partnership, making it timely and will generate an even more attractive shopping experience in the airports.

          About UnionPay International

          UnionPay International (UPI) focuses on the growth and support of UnionPay's global business. In partnership with more than 1000 institutions worldwide, UPI has enabled card acceptance in more than 157 countries and regions outside the Chinese mainland with issuance in 40 countries and regions with over 5 billion cards issued worldwide. UPI provides high quality, cost effective and secure cross-border payment services. As the world's largest cardmember base, UPI ensures convenient local services to a growing number of global UnionPay Cardholders and merchants.

          In ASEAN, UPI has enabled ATM, POS acceptance and card issuance across all the 10 countries. UPI started its business in Malaysia in 2006. UnionPay cards are accepted at over 90% of ATMs and at close to 60% of the local merchants.

          About Malaysia Airports

          Malaysia Airports manages and operates 39 airports in Malaysia and one international airport in Istanbul, Turkey. The 39 airports in Malaysia comprise 5 international, 16 domestic and 18 Short Take-Off and Landing Ports (STOL Ports). It also provides airport management and technical services for the development, operation, maintenance and management in overseas international airports. On November 30, 1999, Malaysia Airports became the first airport company to be listed in Asia.

          KL International Airport (KLIA), its flagship airport was recently voted as the Large Airport of The Year at the CAPA Awards for Excellence in Asia Pacific Aviation 2014. KLIA was also thrice voted as the Best Airport (15-25 million passengers per annum) in the 2005 AETRA awards, 2006 ACI-ASQ awards and 2007 ACI-ASQ awards while the Low Cost Carrier Terminal (LCCT-KLIA) was named CAPA Low Cost Airport of the Year at the CAPA Aviation Awards for Excellence 2006. Malaysia Airports has also received numerous awards that acknowledged its commitment in service, community engagement, corporate responsibility and organisational excellence.

          KLIA has taken a big stride in the realisation of becoming a global integrated hub by launching the Next Generation Hub concept, an initiative aiming to position the ultra-modern airport as a complete hub for all. Its KLIA2 terminal dedicated to low-cost carriers and the world's largest was opened in May 2014.

          MAHB is listed on the Main Board of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

          For more information on MAHB, please visit www.malaysiaairports.com.my

Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress(TM) 2016 of the European Association for the Study of the Liver (EASL)

          - Includes several late breaking and oral presentations from across R&D pipeline

          - Highlights potential of R&D pipeline to deliver several new hepatitis B and C regimens

          Janssen Sciences Ireland UC and certain Janssen affiliates* today announced it will present thirteen abstracts featuring new data on an investigational regimen for treatment of hepatitis B virus (HBV) and approved and investigational regimens for the treatment of hepatitis C virus (HCV) at the upcoming International Liver Congress(TM) of the European Association for the Study of the Liver (EASL 2016). The data to be presented is a reflection of the Janssen Pharmaceutical Companies' ongoing commitment to make hepatitis history by contributing through our research efforts to the elimination of viral hepatitis as a global public health concern.

         

          "Despite recent advances, the global impact of viral hepatitis remains far reaching with significant unmet needs yet to be addressed. We have come a long way in developing cures for hepatitis C, but further innovation is needed to deliver one treatment suitable for all patient types," said Lawrence M. Blatt, PhD, Global Therapeutic Area Head Infectious Diseases and Vaccines, Janssen Research & Development, LLC. "Chronic hepatitis B is a potentially fatal liver disease that requires life-long treatment. There remains no known cure which represents an unmet medical need and we are excited by the opportunity to fully leverage our expertise in this critical disease area in order to bring potentially new treatments to patients".

          Data from Janssen's hepatitis B and C portfolio includes a late breaking abstract on NVR 3-778, a potentially first-in-drug-class HBV capsid assembly inhibitor in treatment-na?ve HBeAG--positive patients, which is also to be featured as part of the official congress press programme.

          Late breaking data for the Phase 3 PLUTO trial with Janssen's protease inhibitor, simeprevir plus sofosbuvir for patients with HCV genotype 4 infection will also be presented. Alongside this, several other Phase 2 and 3 studies which evaluate the efficacy and tolerability for simeprevir in a range of adult patients with varying stages of chronic hepatitis C will be presented.

          Further data on several early-stage investigational regimens in chronic hepatitis C, including new data on Janssen's nucleotide polymerase inhibitor, AL-335, which is currently in a Phase 2a study (NCT02569710) in combination with odalasvir (also called ACHN-3102) and simeprevir, along with Phase 1 data for its nucleotide polymerase inhibitor, JNJ-54257099 will be presented.

          Below is a full list of the data to be presented at the International Liver Congress(TM) 2016. Full poster and oral presentation details can be accessed via the congress website at: https://events.easl.eu/EventProgramme/ILC2016/POSTER.aspx :

          Abstracts in Hepatitis C

          Simeprevir

          - LBP516: Simeprevir plus sofosbuvir for hepatitis C virus genotype 4 infection: a Phase 3, open-label study

          Late-breaking poster presentation, Thursday 14 April at 08:00 and Saturday 16 April at 18:00

          Lead Author: Maria Buti, Hospital Vall d'Hebron and Centro de Investigacion Biomedica en Red en Enfermedades Hepaticas y Digestivas (CIBERehad), Barcelona

          - SAT-264: Pharmacokinetic interactions between simeprevir and ledipasvir in treatment-naive hepatitis C virus genotype 1-infected patients without cirrhosis treated with a simeprevir/sofosbuvir/ledipasvir regimen
Poster presentation, Saturday 16 April, 08:00 - 18:00, Hall 8.1

          Lead Author: S. Bourgeois, Department of Internal Medicine, ZNA Ster, Antwerp

          - THU-215: Deep sequencing results from the Phase 2 IMPACT study of simeprevir in combination with daclatasvir and sofosbuvir in treatment-na?ve and -experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease

          Poster presentation, Thursday 14 April, 08:00 - 18:00, Hall 8.1

          Lead Author: C. Sarrazin, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany

          - THU-214: Consistent simeprevir resistance profile in hepatitis C virus genotype 1-infected patients failing simeprevir interferon-free compared with interferon-containing regimens

          Poster presentation, Thursday 14 April, 08:00 - 18:00, Hall 8.1

          Lead Author: B. Fevery Janssen Infectious Diseases BVBA, Beerse, Belgium

          - SAT-167: Effectiveness of simeprevir-containing regimens among patients with chronic hepatitis C virus in various US practice settings: The SONET study

          Poster presentation, Saturday 16 April, 08:00 - 18:00, Hall 8.1Lead Author: I. Alam, Austin Hepatitis Center, Austin, TX, USA

          - FRI-457: Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin for 12 weeks in subjects with recurrent genotype 1 hepatitis C post-orthotopic liver transplant: The GALAXY study

          Poster presentation, Friday 15 April, 08:00 - 18:00, Hall 8.1

          Lead Author: J.G. O'Leary, Baylor University Medical Center, Dallas, TX, USA

          - SAT-130: Efficacy and tolerability of simeprevir and daclatasvir for 12 or 24 weeks in HCV genotype 1b-infected treatment-na?ve patients with advanced fibrosis or compensated cirrhosis

          Poster presentation, Saturday 16 April, 08:00 - 18:00, Hall 8.1Lead Author: C. Hezode, Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris-Est, France

          - SAT-162: Effectiveness of simeprevir treatment for hepatitis C in real practice: preliminary results from the STIly Italian observational study

          Poster presentation, Saturday 16 April, 08:00 - 18:00, Hall 8.1

          Lead Author: G.B Gaeta, Seconda Universita di Napoli, Napoli

          - SAT-212: Safety of simeprevir-based treatment for hepatitis C in real practice: preliminary results from the STIly observational study

          Poster presentation, Saturday 16 April, 08:00 - 18:00, Hall 8.1

          Lead Author: M. Colombo, Ospedale Maggiore Policlinico, Milano

          JNJ-54257099

          - THU-261: Preclinical characterization of JNJ-54257099 - a potent uridine-based nucleotide polymerase inhibitor in Phase I clinical development for the treatment of chronic hepatitis C

          Poster presentation, Thursday 14 April, 08:00 - 18:00, Hall 8.1

          Lead Author: L. Tambuyzer, Janssen Infectious Diseases, BVBA, Beerse, Belgium

          AL-335

          THU-228: AL-335, A once-daily pangenotypic nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-na?ve genotype 1-4 patients

          Poster presentation, Thursday 14 April, 08:00 - 18:00, Hall 8.1

          Lead Author: E. Berliba, Internal Medicine, State Medical University "N. Testemitanu", Chisinau, Republic of Maldova

          - THU-226:  Pan-genotypic evaluation of AL-335, a clinical stage uridine analogue inhibitor of hepatitis C virus polymerase

          Poster presentation, Thursday 14 April, 08:00 - 18:00, Hall 8.1

          Lead Author: J. Deval*

          Abstracts in Hepatitis B

          NVR 3-778

          - LBO6: NVR 3-778, a first-in-class HBV core inhibitor, alone and in combination with peginterferon (PEGIFN), in treatment-na?ve HBeAG-positive patients: Early reductions in HBV DNA and HBeAG

          Oral presentation is under embargo until Saturday 16 April, 07:00 CET

          Lead Author: Man-Fung Yuen**

          * Alios BioPharma, Inc. and Novira Therapeutics Inc. Both part of the Janssen Pharmaceutical Companies

          **Full session details and data presentation listings for The International Liver Congress(TM) 2016 can be found at http://www.ilc-congress.eu.

          Janssen in Viral Hepatitis 

          At Janssen, our commitment is to make hepatitis history by contributing to the elimination of viral hepatitis as global public health concern. Leveraging our vast research and development experience in viral diseases, we have co-developed two approved treatments for chronic hepatitis C (telaprevir, simeprevir) and are striving to bring forth further transformational medical innovations for chronic hepatitis B and C to improve the lives of all those affected by viral hepatitis.

          We are developing a new combination regimen in hepatitis C which has the potential to treat and cure a broad range of people living with this disease. And seek to overcome the treatment challenges in hepatitis B, such as the requirement for people to require lifelong therapy, with the aim of developing a functional cure.

          With goals like this, there's no time to waste. That is why we partner with organizations around the world, connecting our own expertise with that of others. Because, only together we can Make Hepatitis History.

          About Hepatitis 

          Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide and 350,000 people per year die from the disease globally. When left untreated, hepatitis C can cause significant damage to the liver including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which may include liver failure. Similarly, chronic hepatitis B (HBV) causes approximately 650,000 deaths worldwide from cirrhosis and liver cancer, with approximately 60 percent of hepatocellular carcinoma attributed to hepatitis B infection. Current recommended therapies are unable to cure the infection, requiring most people to continue treatment for life.

          About Janssen Pharmaceutical Companies of Johnson & Johnson

          At Janssen, we are dedicated to addressing some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. For more information, visit http://www.janssen.com or follow @JanssenGlobal.

          Cautions Concerning Forward-Looking Statements

          This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Sciences Ireland UC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.